Biomarker Research最新文献_第10页

A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma. 基于机器学习的预测滤泡性淋巴瘤POD24的模型：中国滤泡性淋巴瘤研讨会的研究。

IF 9.5 2区医学

Biomarker Research Pub Date : 2025-01-03 DOI: 10.1186/s40364-024-00716-4

Jie Zha, Qinwei Chen, Wei Zhang, Hongmei Jing, Jingjing Ye, Huanhuan Liu, Haifeng Yu, Shuhua Yi, Caixia Li, Zhong Zheng, Wei Xu, Zhifeng Li, Zhijuan Lin, Lingyan Ping, Xiaohua He, Liling Zhang, Ying Xie, Feili Chen, Xiuhua Sun, Liping Su, Huilai Zhang, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu

{"title":"A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma.","authors":"Jie Zha, Qinwei Chen, Wei Zhang, Hongmei Jing, Jingjing Ye, Huanhuan Liu, Haifeng Yu, Shuhua Yi, Caixia Li, Zhong Zheng, Wei Xu, Zhifeng Li, Zhijuan Lin, Lingyan Ping, Xiaohua He, Liling Zhang, Ying Xie, Feili Chen, Xiuhua Sun, Liping Su, Huilai Zhang, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu","doi":"10.1186/s40364-024-00716-4","DOIUrl":"https://doi.org/10.1186/s40364-024-00716-4","url":null,"abstract":"Background: Disease progression within 24 months (POD24) significantly impacts overall survival (OS) in patients with follicular lymphoma (FL). This study aimed to develop a robust predictive model, FLIPI-C, using a machine learning approach to identify FL patients at high risk of POD24.Methods: A cohort of 1,938 FL patients (FL1-3a) from seventeen centers nationwide in China was randomly divided into training and internal validation sets (2:1 ratio). XGBoost was utilized to construct the POD24-predicting model, which was internally validated in the validation set and externally validated in the GALLIUM cohort. Key predictors of POD24 included lymphocyte-to-monocyte ratio (LMR), lactate dehydrogenase (LDH) > ULN, low hemoglobin (Hb), elevated beta-2 microglobulin (β2-MG), maximum standardized uptake value (SUVmax), and lymph node involvement. The FLIPI-C model assigned 2 points to LMR and 1 point to each of the other variables.Results: The FLIPI-C model demonstrated superior accuracy (AUC) for predicting POD24 and 3-year overall survival (OS) in both the internal (AUC POD24: 0.764, OS: 0.700) and external validation cohorts (AUC POD24: 0.703, OS: 0.653), compared to existing models (FLIPI, FLIPI-2, PRIMA-PI, FLEX). Decision curve analysis confirmed the superior net benefits of FLIPI-C.Conclusions: Developed using a machine learning approach, the FLIPI-C model offers superior predictive accuracy and utilizes simple, widely available markers. It holds promise for informing treatment decisions and prognostic assessments in clinical practice for FL patients at high risk of POD24.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"13 1","pages":"2"},"PeriodicalIF":9.5,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases. 组织蛋白酶在免疫和炎症反应中的多重作用：对癌症治疗、自身免疫性疾病和传染病的影响。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-31 DOI: 10.1186/s40364-024-00711-9

Kexin Zhao, Yangqing Sun, Shangwei Zhong, Jun-Li Luo

{"title":"The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases.","authors":"Kexin Zhao, Yangqing Sun, Shangwei Zhong, Jun-Li Luo","doi":"10.1186/s40364-024-00711-9","DOIUrl":"10.1186/s40364-024-00711-9","url":null,"abstract":"The cathepsin family comprises lysosomal proteases that play essential roles in various physiological processes, including protein degradation, antigen presentation, apoptosis, and tissue remodeling. Dysregulation of cathepsin activity has been linked to a variety of pathological conditions, such as cancer, autoimmune diseases, and neurodegenerative disorders. Understanding the functions of cathepsins is crucial for gaining insights into their roles in both health and disease, as well as for developing targeted therapeutic approaches. Emerging research underscores the significant involvement of cathepsins in immune cells, particularly T cells, macrophages, dendritic cells, and neutrophils, as well as their contribution to immune-related diseases. In this review, we systematically examine the impact of cathepsins on the immune system and their mechanistic roles in cancer, infectious diseases, autoimmune and neurodegenerative disorders, with the goal of identifying novel therapeutic strategies for these conditions.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"165"},"PeriodicalIF":9.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PCSK9 in T-cell function and the immune response. PCSK9在t细胞功能和免疫应答中的作用。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-31 DOI: 10.1186/s40364-024-00712-8

Yuying Wang, Xiaosheng Fang, Jiarui Liu, Xiao Lv, Kang Lu, Yingxue Lu, Yujie Jiang

引用次数: 0

Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy. 免疫景观中的血小板信号：综合机制与临床治疗。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-31 DOI: 10.1186/s40364-024-00700-y

Mengyao Yan, Zhe Wang, Zhiwei Qiu, Yimin Cui, Qian Xiang

{"title":"Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.","authors":"Mengyao Yan, Zhe Wang, Zhiwei Qiu, Yimin Cui, Qian Xiang","doi":"10.1186/s40364-024-00700-y","DOIUrl":"10.1186/s40364-024-00700-y","url":null,"abstract":"Platelets are essential for blood clotting and maintaining normal hemostasis. In pathological conditions, platelets are increasingly recognized as crucial regulatory factors in various immune-mediated inflammatory diseases. Resting platelets are induced by various factors such as immune complexes through Fc receptors, platelet-targeting autoantibodies and other platelet-activating stimuli. Platelet activation in immunological processes involves the release of immune activation stimuli, antigen presentation and interaction with immune cells. Platelets participate in both the innate immune system (neutrophils, monocytes/macrophages, dendritic cells (DCs) and Natural Killer (NK) cells and the adaptive immune system (T and B cells). Clinical therapeutic strategies include targeting platelet activation, platelet-immune cell interaction and platelet-endothelial cell interaction, which display positive development prospects. Understanding the mechanisms of platelets in immunity is important, and developing targeted modulations of these mechanisms will pave the way for promising therapeutic strategies.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"164"},"PeriodicalIF":9.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor microenvironment and immunotherapy for triple-negative breast cancer. 三阴性乳腺癌的肿瘤微环境与免疫治疗。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-31 DOI: 10.1186/s40364-024-00714-6

Zijie Guo, Ziyu Zhu, Xixi Lin, Shenkangle Wang, Yihong Wen, Linbo Wang, Lili Zhi, Jichun Zhou

{"title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer.","authors":"Zijie Guo, Ziyu Zhu, Xixi Lin, Shenkangle Wang, Yihong Wen, Linbo Wang, Lili Zhi, Jichun Zhou","doi":"10.1186/s40364-024-00714-6","DOIUrl":"10.1186/s40364-024-00714-6","url":null,"abstract":"Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC, with immune checkpoint therapy playing a significant role in comprehensive treatment plans. The tumor microenvironment (TME), comprising immune cells, stromal cells, and various cytokines, plays a crucial role in TNBC progression and response to immunotherapy. The high presence of tumor-infiltrating lymphocytes and immune checkpoint proteins in TNBC indicates the potential of immunotherapeutic strategies. However, the complexity of the TME, while offering therapeutic targets, requires further exploration of its multiple roles in immunotherapy. In this review, we discuss the interaction mechanism between TME and TNBC immunotherapy based on the characteristics and composition of TME, and elaborate on and analyze the effect of TME on immunotherapy, the potential of TME as an immune target, and the ability of TME as a biomarker. Understanding these dynamics will offer new insights for enhancing therapeutic approaches and investigating stratification and prognostic markers for TNBC patients.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"166"},"PeriodicalIF":9.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11689763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies. 慢性淋巴细胞白血病的遗传畸变和信号通路相互作用：从发病机制到治疗策略。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-28 DOI: 10.1186/s40364-024-00710-w

Anna Sobczyńska-Konefał, Monika Jasek, Lidia Karabon, Emilia Jaskuła

{"title":"Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.","authors":"Anna Sobczyńska-Konefał, Monika Jasek, Lidia Karabon, Emilia Jaskuła","doi":"10.1186/s40364-024-00710-w","DOIUrl":"10.1186/s40364-024-00710-w","url":null,"abstract":"Chronic lymphocytic leukemia (CLL) is prevalent in adults and is characterized by the accumulation of mature B cells in the blood, bone marrow, lymph nodes, and spleens. Recent progress in therapy and the introduction of targeted treatments [inhibitors of Bruton's tyrosine kinase (BTKi) or inhibitor of anti-apoptotic B-cell lymphoma-2 (Bcl-2i) protein (venetoclax)] in place of chemoimmunotherapy have significantly improved the outcomes of patients with CLL. These advancements have shifted the importance of traditional predictive markers, leading to a greater focus on resistance genes and reducing the significance of mutations, such as TP53 and del(17p). Despite the significant progress in CLL treatment, some patients still experience disease relapse. This is due to the substantial heterogeneity of CLL as well as the interconnected genetic resistance mechanisms and pathway adaptive resistance mechanisms to targeted therapies in CLL. Although the knowledge of the pathomechanism of CLL has expanded significantly in recent years, the precise origins of CLL and the interplay between various genetic factors remain incompletely understood, necessitating further research. This review enhances the molecular understanding of CLL by describing how BCR signalling, NF-κB PI3K/AKT, and ROR1 pathways sustain CLL cell survival, proliferation, and resistance to apoptosis. It also presents genetic and pathway-adaptive resistance mechanisms in CLL. Identifying B-cell receptor (BCR) signalling as a pivotal driver of CLL progression, the findings advocate personalized treatment strategies based on molecular profiling, emphasizing the need for further research to unravel the complex interplay between BCR signalling and its associated pathways to improve patient outcomes.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"162"},"PeriodicalIF":9.5,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer. 循环T细胞免疫表型分析在肺癌早期诊断中的应用。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-26 DOI: 10.1186/s40364-024-00713-7

Sung-Woo Lee, Young Ju Kim, Kyung Na Rho, Saei Jeong, Jeong Eun Noh, Hee-Ok Kim, Hyun-Ju Cho, Ju Sik Yun, In-Jae Oh, Jae-Ho Cho

{"title":"Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer.","authors":"Sung-Woo Lee, Young Ju Kim, Kyung Na Rho, Saei Jeong, Jeong Eun Noh, Hee-Ok Kim, Hyun-Ju Cho, Ju Sik Yun, In-Jae Oh, Jae-Ho Cho","doi":"10.1186/s40364-024-00713-7","DOIUrl":"10.1186/s40364-024-00713-7","url":null,"abstract":"The immune system continuously interacts with tumors, possibly leading to systemic alterations in circulating immune cells. However, the potential of these cancer-associated changes for diagnostic purposes remains poorly explored. To investigate this, we conducted a comprehensive flow cytometric analysis of 452 peripheral blood mononuclear cell (PBMC) samples from 206 non-small-cell lung cancer (NSCLC) patients, 100 small-cell lung cancer (SCLC) patients, 94 healthy individuals, and 52 benign lung disease (BLD) patients. We focused specifically on circulating T cells, given their close interaction with tumors, and initially assessed 93 T-cell features from the flow cytometric analysis. Using a feature selection protocol, we identified five T-cell features in peripheral blood with strong diagnostic relevance. Notably, while individual alterations in these features lacked cancer specificity, simultaneous alterations were uniquely indicative of lung cancer. To comprehensively analyze these features, we developed a scoring model, \"IMmunoPhenotypic Analysis for Cancer deTection (IMPACT).\" Comprehensive analysis using the five features (IMPACT-5) demonstrated high cancer specificity and biomarker efficacy, as evidenced by the high area under the receiver operating characteristic curve values for lung cancer patients (0.9187, 0.9277, and 0.9363 for stage I NSCLC, stage IV NSCLC, and SCLC patients, respectively), in stark contrast to BLD patients (0.5212). These findings suggest that comprehensive analysis of cancer-associated changes in circulating T cells can effectively detect lung cancer from its early stages, proposing immunophenotypic analysis of circulating T cells as an innovative liquid biopsy-based diagnostic biomarker.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"161"},"PeriodicalIF":9.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decoding burn trauma: biomarkers for early diagnosis of burn-induced pathologies. 解码烧伤创伤：早期诊断烧伤病理的生物标志物。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-23 DOI: 10.1186/s40364-024-00707-5

Fadi Khalaf, Daniella Touma, Alexandra Pappas, Lareina Hatim, Stephanie Wojtowicz-Piotrowski, Marc G Jeschke

{"title":"Decoding burn trauma: biomarkers for early diagnosis of burn-induced pathologies.","authors":"Fadi Khalaf, Daniella Touma, Alexandra Pappas, Lareina Hatim, Stephanie Wojtowicz-Piotrowski, Marc G Jeschke","doi":"10.1186/s40364-024-00707-5","DOIUrl":"10.1186/s40364-024-00707-5","url":null,"abstract":"Burn injuries represent a significant global challenge due to their multifaceted nature, characterized by a complex cascade of metabolic and immune dysfunction that can result in severe complications. If not identified and managed promptly, these complications can escalate, often leading to fatal outcomes. This underscores the critical importance of timely and precise diagnosis. Fortunately, biomarkers for burn-induced pathologies and outcomes have emerged as powerful diagnostic and prognostic tools. These biomarkers enable early diagnosis and intervention, facilitate risk assessment, support patient-specific treatment, monitoring of disease progression, and therapeutic efficacy, ultimately contributing to improved patient outcomes. However, while previous studies have provided valuable biomarkers for the detection of burn-induced pathologies, many of these were constrained by the techniques and sample sizes available at the time, which can limit the generalizability of the findings. This review highlights numerous biomarkers studied in the literature to date, underscoring the need to replicate these findings in more diverse and representative populations. It also emphasizes the importance of advancing research efforts to develop more efficient, accurate, and cost-effective approaches for integrating biomarkers into clinical practice.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"160"},"PeriodicalIF":9.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications. 血液恶性肿瘤中的LILRB家族：预后关联、机制考虑和治疗意义。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-19 DOI: 10.1186/s40364-024-00705-7

Alan Hodges, Rachel Dubuque, Shu-Hsia Chen, Ping-Ying Pan

{"title":"The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications.","authors":"Alan Hodges, Rachel Dubuque, Shu-Hsia Chen, Ping-Ying Pan","doi":"10.1186/s40364-024-00705-7","DOIUrl":"10.1186/s40364-024-00705-7","url":null,"abstract":"The leukocyte immunoglobulin-like receptor B (LILRB) proteins, characterized by their transmembrane nature and canonical immunoreceptor tyrosine-based inhibitory motifs (ITIM) signaling, play a pivotal role in maintaining immune homeostasis and are implicated in the pathogenesis of various disease states. This comprehensive review will focus on the intricate involvement of the LILRB family in hematologic malignancies. These receptors have emerged as valuable diagnostic and prognostic biomarkers in leukemia, lymphoma, and myeloma. Beyond their prognostic implications, LILRBs actively shape the immune microenvironment and directly influence the disease pathogenesis of hematologic malignancies. Furthermore, their identification as potential therapeutic targets offer a promising avenue for precision medicine strategies in the treatment of these disorders. Currently, multiple LILRB directed therapies are in the preclinical and clinical trial pipelines. This review underscores the multifaceted role of the LILRB family in hematologic malignancies, highlighting their significance from diagnostic and prognostic perspectives to their broader impact on disease pathophysiology and as valuable therapeutic targets.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"159"},"PeriodicalIF":9.5,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy. mRNA癌症疫苗从实验室到床边：癌症免疫治疗的新时代。

IF 9.5 2区医学

Biomarker Research Pub Date : 2024-12-18 DOI: 10.1186/s40364-024-00692-9

Alireza Shariati, Pouria Khani, Farzad Nasri, Hamed Afkhami, Arya Khezrpour, Sina Kamrani, Fatemeh Shariati, Sajad Alavimanesh, Mohammad Hossein Modarressi

{"title":"mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy.","authors":"Alireza Shariati, Pouria Khani, Farzad Nasri, Hamed Afkhami, Arya Khezrpour, Sina Kamrani, Fatemeh Shariati, Sajad Alavimanesh, Mohammad Hossein Modarressi","doi":"10.1186/s40364-024-00692-9","DOIUrl":"10.1186/s40364-024-00692-9","url":null,"abstract":"Harnessing the power of the immune system to target cancer cells is one of the most appealing approaches for cancer therapy. Among these immunotherapies, messenger ribonucleic acid (mRNA) cancer vaccines are worthy of consideration, as they have demonstrated promising results in clinical trials. These vaccines have proven to be safe and well-tolerated. They can be easily mass-produced in a relatively short time and induce a systemic immune response effective against both the primary tumor and metastases. Transcripts encoding immunomodulatory molecules can also be incorporated into the mRNA, enhancing its efficacy. On the other hand, there are some challenges associated with their application, including mRNA instability, insufficient uptake by immune cells, and intrinsic immunogenicity, which can block mRNA translation. Many innovations have been suggested to overcome these obstacles, including structural modification (such as 5' cap modification), optimizing delivery vehicles (especially dendritic cells (DCs) and nanoparticles), and using antigens that can enhance immunogenicity by circumventing tolerance mechanisms. A popular approach is to combine mRNA cancer vaccines with traditional and novel cancer treatments like chemotherapy, radiotherapy, and immune checkpoint blockade (ICB). They are most efficacious when combined with other therapies like ICBs. There is still a long way to go before these vaccines enter the standard of care for cancer patients, but with the incredible pace of development in this field, their clinical application will soon be witnessed. This review highlights the recent advances and challenges of mRNA cancer vaccines. Finally, some of the most prominent clinical applications of these vaccines will be reviewed.","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"157"},"PeriodicalIF":9.5,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0